Author |
김상은(Sang Eun Kim),송영기(Young Kee Shong),조보연(Bo Youn Cho),김노경(Noe Kyeong Kim),고창순(Chang Soon Koh),이문호(Mun Ho Lee),홍성운(Seong Woon Hong),홍기석(Kee Suk Hong), |
Abstract |
To evaluate the performance characteristics of CA 19-9
radioimmunoassay and the clinical significance of serum
CA 19-9 assay in patients with malignancy, serum. CA
19-9 levels were measured by radioimmunoassay using
monoclonal antibody in 135 normal controls, 81 patients
with various untreated malignancy, 9 patients of
postoperative colon cancer without recurrence and 20
patients with benign gastrointestinal diseases, who
visited Seoul National University Hospital from June,
1984 to March, 1985. The results were as follows; 1)
The CA 19-9 radioimmunoassay was simple to perform and
can be completed in one workd day. And the between-
assay reproducibility and the assay recovery were both
excellent. 2) The mean serum CA 19-9 level in 135
normal controls was 8.4±4.2U/mL. Normal upper limit of
serum CA 19-9 was defined as 21.0U/mL. 4 out of 135
(3.0%) normal controls showed elevated CA 19-9 levels
above the normal upper limit. 3) One out of 20 (5.0%)
patients with benign gastrointestinal diseases showed
elevated serum CA 19-9 level above the normal upper
limit. 4) In 81 patients with various untreated
malignancy, 41 patients (50.6%) showed elevated serum
CA 19-9 levels. 66.7% of 18 patients with colorectal
cancer, 100% of 2 patients with pancreatic cancer, 100%
of 3 patients with common bile duct cancer, 47.1% of 17
patients with stomach cancer, 28.6% of 28 patients with
hepatoma and 60.0% of 5 gastrointestinal tract cancers
showed elevated serum CA 19-9 levels. 5) The
sensitivities of serum CA 19-9 related to
respectability in colorectal and stomach cancer were
33.3% in resectable colorectal cancer, 83.3% in
unresectable colorectal cancer, 41.7% in resectable
stomach cancer, 60.0% in unresectable stomach cancer
respectively. 6) The sensitivity of serum CA 19-9 in 9
patients of postoperative colorectal cancer without
recurrence were 33.3% and significantly decressed
compared with that of untreated colorectal cancer,
66.7% (p〈0.05). 7) In Patients with colorectal cancer,
simultaneous measurement of serum CA 19-9 and serum CEA
levels increased sensitivities. From above results, we
concluded that serum CA 19-9 radiommunoassay is simple
to perform and reproducible, and is a useful indicator
reflecting tumor exent and responses to the treatment
in patients with malignancy. |